|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world. |
| 公司地址
| 9, rue de Bitbourg, Luxembourg, LUX, L-1273 |
| 電話號碼
| +352 4224500 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.alvotech.com |
| 員工數量
| 1460 |
| Ms. Linda Jonsdottir |
Chief Financial Officer |
-- |
31/03/2026 |
| Mr. Joseph E. McClellan |
Chief Operating Officer |
-- |
31/03/2026 |
| Mr. Vilhelm Robert Wessman |
Executive Chairman of the Board and Chief Executive Officer |
-- |
31/03/2026 |
| Ms. Tanya Zharov |
General Counsel |
-- |
31/03/2026 |
|
|
| Ms. Lisa Graver |
Independent Director |
31/03/2026 |
| Ms. Ann Merchant |
Independent Director |
31/03/2026 |
| Mr. Arni Hardarson |
Independent Director |
31/03/2026 |
| Mr. Vilhelm Robert Wessman |
Executive Chairman of the Board and Chief Executive Officer |
31/03/2026 |
| Mr. Richard Davies |
Deputy Chairman of the Board |
31/03/2026 |
| Mr. Hjorleifur Palsson |
Independent Director |
31/03/2026 |
| Mr. Tomas Ekman |
Director |
31/03/2026 |
|
|
|
|
